VVOS — Vivos Therapeutics, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1716166 ·
Last close
$0.28
Market Cap
$5.57M
52W High
$1.36
52W Low
$0.26
ADV30
2,015,348
Next earnings
2026-11-16
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 5,141,000 3,059,000 -6,615,000 -7,751,000 25,043,000 2,110,000 26,310,000
Dec 2025 3,824,000 2,988,000 -6,382,000 -6,954,000 25,152,000 2,029,000 26,702,000
Sep 2025 6,783,000 3,937,000 -4,734,000 -5,400,000 25,644,000 3,087,000 23,112,000
Jun 2025 3,820,000 2,110,000 -4,865,000 -5,013,000 26,033,000 4,402,000 21,450,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-17,477,000
Investing CF
$-7,422,000
Financing CF
$24,667,000
CapEx
$-2,442,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.01
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-133,039,000
Inventory
Receivables
$1,769,000
ST Investments
EBIT TTM
$-22,596,000
Pretax Income TTM
$-25,118,000
Interest Exp TTM
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$20,902,000
EBITDA
$-20,763,000
Free Cash Flow
$-8,534,250
Enterprise Value
$17,640,052
Total Cash
$1,774,000
Total Debt
$12,505,000
Shares Out
20,118,023
Trailing EPS
$-1.88
Book Value
$0.31
ROE
-8585.3%
ROA
-56.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 17,443,000 -19,894,000 -21,230,000 25,152,000 26,702,000 -15,263,000
Dec 2024 15,031,000 -11,171,000 -11,136,000 15,284,000 7,330,000 -12,691,000
Dec 2023 13,801,000 -17,296,000 -13,583,000 10,730,000 10,319,000 -11,946,000
Dec 2022 16,024,000 -25,031,000 -23,845,000 13,720,000 8,919,000 -19,587,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.82

Peers — same industry

TickerNameMarket CapLastDaily %
CLGN CollPlant Biotechnologies Ltd $5.69M $0.30
WOK WORK Medical Technology Group LTD $5.36M $2.22
MHUAF Meihua International Medical Technologies Co., Ltd. $5.83M $6.82
AMIX Autonomix Medical, Inc. $5.21M $5.37
XAIR Beyond Air, Inc. $4.83M $4.91

News headlines (Yahoo Finance, 1h cache)

Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers
2026-08-25 12:45 · Yahoo
Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts
2026-08-17 11:05 · Yahoo
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates
2026-08-14 21:40 · Yahoo
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
2026-08-14 12:45 · Yahoo
Vivos Therapeutics Secures New U.S. Patent Expanding Protection for Vivos CARE Technology
2026-08-05 14:48 · Yahoo
Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology
2026-08-05 12:30 · Yahoo
Vivos Therapeutics (VVOS) Stock Sees Fair Value Moves Lower As Analysts Reset Growth Assumptions
2026-07-03 13:17 · Yahoo
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
2026-06-22 12:30 · Yahoo
Vivos Therapeutics Plans to File for Proposed Rights Offering
2026-06-11 13:11 · Yahoo
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
2026-06-11 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.